Exploring the role of coagulation-related genes in renal cell carcinoma: Implications for tumor microenvironment and prognostic biomarkers.

PURPOSE: Clear cell renal cell carcinoma (ccRCC) frequently progresses to advanced stages due to tumor thrombus (TTs) formation. In this study, we aimed to investigate the role of coagulation-related pathway activation in the progression of ccRCC. METHODS: Consensus clustering was used to identify coagulation-related molecular clusters of ccRCC patients from The Cancer Genome Atlas Program (TCGA) database. The function of coagulation and its correlation with the immune microenvironment were investigated. Protein-protein interactions and differential expression analysis were used to identify the key gene, which was verified by external experiments. The coagulation-associated risk score was constructed by cox proportional hazards regression. RESULTS: Notable disparities were detected in immune characteristics, prognostic differentiation and drug sensitivity between two coagulation-related clusters. Through the integration of clinical stage significance and protein-protein interactions, the key gene MMP9 was screened and it was significantly correlated with CD4+T cells, CD8+T cells and Treg cells. A coagulation-related risk score prognostic model was developed in the Cancer Genome Atlas (TCGA) cohort for risk stratification and prognosis prediction. The prognostic predictive values of the coagulation-related risk score were further authenticated in both TCGA-KIRC and E-MTAB-1980 cohorts. CONCLUSION: There is an obvious correlation between the coagulation and the tumor microenvironment in ccRCC. As a key coagulation-related gene, MMP9 may promote the progression of renal cell carcinoma by influencing immune infiltration of CD8+T cells and Treg cells. Additionally, the risk score could be used as a durable prognostic biomarker, which could assist in clinical decision making for ccRCC patients.

Single-ended self-calibration high-accuracy Raman distributed temperature sensing based on multi-core fiber.

Raman distributed temperature sensing (RDTS) obtains the temperature information by measuring the intensities of Raman scattering lights. The anti-stokes only RDTS can avoid the error caused by wavelength-dependent loss and dispersion. However, to eliminate temperature-independent intensity variations, single-wavelength demodulation generally adopts the double-ended detection scheme. This requires two optical fibers or one fiber to be folded into a loop, which is inconvenient in practical applications. Moreover, the temperature accuracy of such a scheme is lower than the conventional single-ended system, so it has not been widely used. Here, we propose and experimentally demonstrate a multi-core fiber (MCF) based RDTS system. A single-ended loop structure is achieved by connecting two cores at the far end of the MCF with a fan-in/fan-out device. By measuring the backscattered anti-stokes lights in the two cores, the results can be self-calibrated to eliminate the influence of temperature-independent light intensity changes. Besides, the results can be improved by averaging the temperatures of the two cores due to the spatial consistency of the MCF. Moreover, to further improve the temperature uncertainty, we employ the one-dimensional denoising convolutional neural network. Finally, a maximum temperature uncertainty of 1.4 °C is achieved over a 10 km MCF with a 3 m spatial resolution.

[Increased level of prostate-specific antigen: a diagnostic marker of hyperandrogenism women].

OBJECTIVE: To determine whether the increased level of serum prostate-specific antigen (PSA) could be used as a diagnostic marker of hyperandrogenism in women. METHODS: Forty-five female patients with hyperandrogenism and 50 healthy control women were detected for the levels of serum PSA, testosterone (T), sex hormone binding globulin (SHBG) and dehydroepiandrosterone sulfate (DHEA-S). The results were statistically analyzed. RESULTS: The level of serum PSA was found to be significantly higher in the hyperandrogenism patients than in the healthy controls (9.72 +/- 1.39 pg/ml vs 3.56 +/- 0.44 pg/ml, P < 0.01), and it showed a weak positive correlation with T (r = 0.226, P < 0.05) and DHEA-S (r = 0.255, P < 0.05), and a weak negative correlation with SHBG (r = -0,228, P < 0.05). CONCLUSION: The increased level of PSA could be used as a diagnostic marker of hyperandrogenism in females.

[Association among lipids, leptin and leptin receptor polymorphisms with risk of breast cancer].

OBJECTIVE: To evaluate the association between serum level of leptin and leptin receptor gene (LEPR) polymorphism and patients with breast cancer. METHODS: LEPR G1n223Arg polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism in 94 patients with breast cancer and 128 healthy controls. The level of leptin were analyzed by enzyme linked immunosorbent assay. RESULTS: In univariate regression analyses, we found serum level of leptin and LEPR Gin223Arg genotype polymorphism were significantly higrer than those of the controls (P < 0.05-0.001, respectively). Through multivariable analyses, we found that increased risk estimates for breast cancer were among those with leptin level (OR = 1.53, 95% CI: 1.13-2.07, P = 0.006), LEPR Gin223Arg genotype (OR = 4.87, 95%CI:1.30-18.22, P = 0.019), WHR (OR = 3.68, 95% CI: 1.34-10.11, P = 0.011). CONCLUSION: Results from this study suggested that LEPR Gln233Agr polymorphism, the elevated WHR and serum level of leptin might be correlated with increased risk of breast cancer.

[Development of radioimmunoassay for human sperm protein 17].

OBJECTIVE: To develop a method of radioimmunoassay for human sperm protein 17(Sp17) determination. METHODS: Anti-recombinant human Sp17 antibody was prepared, the labeling of 125I-rhSp17 performed by chloramine T method, and radioimmunoassay of Sp17 developed. RESULTS: The assay range was 3.3 to approximately 800 microg/L, the sensitivity was 2.0 microg/L, and the intra- and inter-assay coefficients of variation (CV) were 7.5% to approximately 9.8% and 8.2% to approximately 13.2%, respectively. The serum Sp17 level in normal subjects was (15.60 +/- 7.66) microg/L (n = 59). CONCLUSION: This radioimmunoassay of Sp17 fulfills the reasonable requirements of clinical routine and scientific studies in terms of specificity, sensitivity and practicability. Measurement of Sp17 concentration is useful for assessing its native distribution and aberrant expression.

[Detection of free testosterone in the serum and semen of idiopathic oligospermia patients and its significance].

OBJECTIVE: To detect free testosterone (FT) in the serum and semen of patients with idiopathic oligospermia, and further analyze the relationship between FT and idiopathic oligospermia. METHODS: Blood samples were collected from the males of a normal control group (n = 44) and an idiopathic oligospermia group (n = 44) at 8:00-10:00 a.m.. Semen samples were collected from the males of a normal control group (n = 30) and an idiopathic oligospermia group (n = 37) at the same time. Sperm density was detected by routine semen analysis, and FT in the serum and semen was detected by RIA. RESULTS: There was no significant difference in the serum concentrations of FT between the groups of normal control [(97.50 +/- 46.96) pmol/L] and idiopathic oligospermia [(94.88 +/- 42.04) pmol/L], P > 0.5. But the difference was significant in the semen concentrations of FT between the groups of normal control [(2.01 +/- 0.32) pmol/L] and idiopathic oligospermia [(0.52 +/- 0.44) pmol/L], P < 0.01. CONCLUSION: Measurement of semen FT concentration could early reflect the function of the testis, which contributes to the early diagnosis and treatment of idiopathic oligospermia.